ŠPINAR, Jindřich, Jiří JARKOVSKÝ, Lenka ŠPINAROVÁ, Jiří VÍTOVEC, Ales LINHART, Petr WIDIMSKY, Roman MIKLÍK, Kamil ZEMAN, Jan BELOHLAVEK, Filip MALEK, Cestmir CIHALIK, Jiří ŠPÁC, Marián FELŠŐCI, Petr OSTADAL, Ladislav DUŠEK, Jiri KETTNER, Jan VACLAVIK, Simona LITTNEROVÁ, Zdeněk MONHART, Josef MALEK and Jiří PAŘENICA. Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. ESC Heart Failure. San Francisco: Wiley Periodicals, 2017, vol. 4, No 1, p. 8-15. ISSN 2055-5822. Available from: https://dx.doi.org/10.1002/ehf2.12105.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial
Authors ŠPINAR, Jindřich (203 Czech Republic, guarantor, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Jiří VÍTOVEC (203 Czech Republic, belonging to the institution), Ales LINHART (203 Czech Republic), Petr WIDIMSKY (203 Czech Republic), Roman MIKLÍK (203 Czech Republic), Kamil ZEMAN (203 Czech Republic), Jan BELOHLAVEK (203 Czech Republic), Filip MALEK (203 Czech Republic), Cestmir CIHALIK (203 Czech Republic), Jiří ŠPÁC (203 Czech Republic, belonging to the institution), Marián FELŠŐCI (703 Slovakia), Petr OSTADAL (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Jiri KETTNER (203 Czech Republic), Jan VACLAVIK (203 Czech Republic), Simona LITTNEROVÁ (203 Czech Republic, belonging to the institution), Zdeněk MONHART (203 Czech Republic), Josef MALEK (203 Czech Republic) and Jiří PAŘENICA (203 Czech Republic, belonging to the institution).
Edition ESC Heart Failure, San Francisco, Wiley Periodicals, 2017, 2055-5822.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/17:00096071
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/ehf2.12105
UT WoS 000397197700002
Keywords in English Acute heart failure; Mortality; Blood pressure; Vasodilator therapy; AHEAD registry
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 17/5/2018 15:35.
Abstract
The randomized clinical trial RELAX-AHF demonstrated a positive effect of vasodilator therapy with serelaxin in the treatment of AHF patients. The aim of our study was to compare clinical characteristics and outcomes of patients from the AHEAD registry who met criteria of the RELAX-AHF trial (relax-comparable group) with the same characteristics and outcomes of patients from the AHEAD registry who did not meet those criteria (relax-non-comparable group), and finally with characteristics and outcomes of patients from the RELAX-AHF trial. Methods and results A total of 5856 patients from the AHEAD registry (Czech registry of AHF) were divided into two groups according to RELAX-AHF criteria: relax-comparable (n = 1361) and relax-non-comparable (n = 4495). As compared with the relax-non-comparable group, patients in the relax-comparable group were older, had higher levels of systolic and diastolic blood pressure, lower creatinine clearance, and a higher number of comorbidities. Relax-comparable patients also had significantly lower short-term as well as long-term mortality rates in comparison to relax-non-comparable patients, but a significantly higher mortality rate in comparison to the placebo group of patients from the RELAX-AHF trial. Using AHEAD score, we have identified higher-risk patients from relax-comparable group who might potentially benefit from new therapeutic approaches in the future. Conclusions Only about one in five of all evaluated patients met criteria for the potential treatment with the new vasodilator serelaxin. AHF patients from the real clinical practice had a higher mortality when compared with patients from the randomized clinical trial.
Links
MUNI/A/1362/2015, interní kód MUName: Neurohumorální profil a prognóza pacientů s chronickým srdečním selháním
Investor: Masaryk University, Category A
PrintDisplayed: 5/5/2024 11:49